Watershed Asset Management L.L.C. Boosts Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Watershed Asset Management L.L.C. increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 27.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,900 shares of the biotechnology company’s stock after buying an additional 1,900 shares during the period. Repligen accounts for 1.9% of Watershed Asset Management L.L.C.’s holdings, making the stock its 11th biggest position. Watershed Asset Management L.L.C.’s holdings in Repligen were worth $1,600,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. abrdn plc increased its position in shares of Repligen by 1.4% in the fourth quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock valued at $934,000 after buying an additional 71 shares in the last quarter. Signaturefd LLC increased its holdings in Repligen by 44.1% in the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 86 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Repligen by 14.8% in the 3rd quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 87 shares in the last quarter. Daiwa Securities Group Inc. raised its position in Repligen by 3.2% during the third quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock worth $509,000 after acquiring an additional 100 shares during the period. Finally, State of Michigan Retirement System lifted its holdings in Repligen by 0.8% during the fourth quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $2,239,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Up 8.8 %

Repligen stock traded up $13.80 during trading on Tuesday, reaching $171.28. 928,604 shares of the company were exchanged, compared to its average volume of 538,659. The stock’s 50 day simple moving average is $186.62 and its two-hundred day simple moving average is $173.56. The company has a market capitalization of $9.56 billion, a P/E ratio of 237.89, a PEG ratio of 5.15 and a beta of 1.02. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The business had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. During the same quarter in the previous year, the firm earned $0.68 EPS. The company’s quarterly revenue was down 16.6% compared to the same quarter last year. On average, equities research analysts expect that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock worth $5,039,532 in the last ninety days. 1.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Stifel Nicolaus upped their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. KeyCorp increased their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.